Obesity pharmacotherapy research updates
Results are from a 64-week medical study of 307 adults with obesity (BMI 30 kg/m 2 ), or with overweight (BMI 27 kg/m 2 ) and at least one weight-related medical problems, including high blood pressure or high cholesterol
For most research protocols, 4-6 sprays per day are needed
In the past five years, research has found that GLP-1 drugs can lower the risk of a number of obesity-related chronic diseases such as heart disease, chronic kidney disease, sleep disorders, osteoarthritis and even certain cancers, with one study finding that people taking GLP-1 drugs had a lower risk of developing 42 different diseases than those given their usual medicines
Recommendations are based on provider evaluation, medical history, goals, and clinical appropriateness